Home Stock

Stock Research: Harmony Biosciences Holdings

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Harmony Biosciences Holdings

NMQ:HRMY US4131971040
79
  • Value
    49
  • Growth
    70
  • Safety
    Safety
    55
  • Combined
    72
  • Sentiment
    91
  • 360° View
    360° View
    79
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on therapies for rare and other neurological diseases. Its main business is developing and commercializing treatments like WAKIX for narcolepsy, and investigational compounds like HBS-102, ZYN002, EPX-100, and EPX-200 for conditions such as Fragile X syndrome, 22q11.2 deletion syndrome, and epilepsy. The company operates in the pharmaceutical and neuroscience sectors, with product development primarily in neurological disease therapies. In the last fiscal year, the company had a market cap of $2010 million, profits of $558 million, and revenue of $715 million.

more

ANALYSIS: With an Obermatt 360° View of 79 (better than 79% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Harmony Biosciences Holdings are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Harmony Biosciences Holdings. The consolidated Growth Rank has a good rank of 70, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 70% of competitors in the same industry. The consolidated Safety Rank at 55 means that the company has a financing structure that is safer than 55% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 91, which means that professional investors are more optimistic about the stock than for 91% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 49, meaning that the share price of Harmony Biosciences Holdings is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 51% of alternative stocks in the same industry. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Medium
Website harmonybiosciences.com
Index
NASDAQ
Harmony Biosciences Holdings stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Nov-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 32 34 17
Growth
70 91 51 100
Safety
Safety
55 86 43 43
Sentiment
91 96 83 100
360° View
360° View
79 98 34 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
18 40 17 81
Opinions Change
87 70 69 50
Pro Holdings
n/a 100 82 92
Market Pulse
91 83 95 90
Sentiment
91 96 83 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 32 34 17
Growth
70 91 51 100
Safety Safety
55 86 43 43
Combined
72 96 59 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
76 41 31 28
Price vs. Earnings (P/E)
28 67 85 64
Price vs. Book (P/B)
53 31 18 4
Dividend Yield
1 1 1 1
Value
49 32 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
66 74 82 81
Profit Growth
96 39 20 100
Capital Growth
17 97 91 94
Stock Returns
69 71 17 67
Growth
70 91 51 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
35 56 49 23
Refinancing
25 49 53 21
Liquidity
97 82 100 100
Safety Safety
55 86 43 43

Similar Stocks

Discover high‑ranked alternatives to Harmony Biosciences Holdings and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

AngloGold Ashanti

NYQ:AU
Country: USA
Industry: Gold Production
Size: X-Large
Full Stock Analysis

Toll Brothers

NYQ:TOL
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews